 The BRAF mutation is reported to be present in approximately 50 of papillary thyroid carcinomas PTC. The mutation has been associated with poor prognosis and more advanced disease stage. Therefore, pre-operative detection of the BRAF-V600E mutation may be of clinical interest in order to individualize treatment of patients with BRAF positive PTC. 